Genius Sports heads into its August 6 earnings print with short sellers retreating, options skewing decisively bullish, and a fresh round of analyst target upgrades — yet the stock at $6.65 still sits well below what most of the Street thinks it's worth.
The short interest angle is the clearest starting point for understanding how sentiment has shifted. At 12.1% of the free float, the short position remains substantial — nearly 29 million shares — but it has fallen roughly 4.4% over the past week and is now easing from a one-month peak that saw shorts climb nearly 47% higher than late-May levels. The retreat in borrowing pressure matches the broader price recovery: GENI has gained 3.6% on the week and 9% over the past month. Critically, the borrow market itself is not stressed. Availability is generous at 266%, meaning there are more than two and a half shares available to lend for every share already shorted — well into "normal" territory for a stock of this size. Cost to borrow is running below 0.5%, essentially free. The practical read is that shorts are trimming positions without any mechanical squeeze forcing their hand; this is discretionary covering, not a liquidity crunch.
Options positioning adds texture to the bullish tilt. The put/call ratio has dropped to 0.041, nearly 1.7 standard deviations below its 20-day average of 0.047 — and near the lowest level in the past year. That's an unusually lopsided setup: call open interest dominates, pointing to positioning for further upside rather than hedging against a drawdown. With earnings six weeks out, traders appear to be leaning into the recovery rather than protecting against it, a configuration that reinforces the covering story in short interest.
The Street is cautiously constructive but not uniformly so. Analyst activity this week captures the tension neatly. Stifel raised its target to $7 from $5 while holding a Hold rating — a notable lift but still barely above the current price. Wells Fargo, meanwhile, trimmed its target to $8 from $9 while keeping an Overweight. Freedom Capital Markets initiated fresh coverage with a Buy and a $9 target. The combined signal: bulls outnumber bears by fifteen to zero on ratings, with a consensus mean target of just over $10 — implying roughly 52% upside from current levels. The valuation backdrop supports that optimism to a degree. EV/EBITDA has compressed to 4.2x and the stock trades at about 2.2x book, both multiples that have drifted lower over the past 30 days as the price recovered more slowly than earnings estimates improved. The EPS momentum scores are striking: 89th percentile on 30-day momentum and 97th percentile on a 90-day basis, suggesting forward estimates have been revised sharply higher even as the stock lagged.
One ownership move worth noting is Glenview Capital Management, which added over 7.9 million shares in its most recently reported period — building a 5.15% stake that makes it one of the three largest institutional holders. Shapiro Capital Management added an even larger block of 8.2 million shares. Both moves suggest active managers took the opportunity during the stock's earlier weakness to build meaningful positions, adding a layer of institutional conviction that underpins the current recovery.
Historically, GENI has had a mixed response to earnings releases. The most recent Q1 print in May produced no same-day move at all, with the stock drifting 5.5% lower over the following five sessions. The prior comparable quarter showed a sharp 10.4% single-day gain. The variance is wide enough that the August 6 result could move the stock materially in either direction — the bull case resting on whether Betting Technology growth continues to accelerate and media programmatic gains hold, while the bear case centres on the dissolution of the Sports Technology segment and whether remaining revenue streams can absorb the shortfall. With DKNG and FLUT both down 5-7% on the week while GENI held its gains, the relative strength itself becomes a data point worth tracking as the print approaches.
See the live data behind this article on ORTEX.
Open GENI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
